JP2016511279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511279A5 JP2016511279A5 JP2015562218A JP2015562218A JP2016511279A5 JP 2016511279 A5 JP2016511279 A5 JP 2016511279A5 JP 2015562218 A JP2015562218 A JP 2015562218A JP 2015562218 A JP2015562218 A JP 2015562218A JP 2016511279 A5 JP2016511279 A5 JP 2016511279A5
- Authority
- JP
- Japan
- Prior art keywords
- payload
- immunoligand
- antibody
- complex
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 8
- 231100000765 toxin Toxicity 0.000 claims description 8
- 108700012359 toxins Proteins 0.000 claims description 8
- 108090000279 Peptidyltransferases Proteins 0.000 claims description 7
- 230000003197 catalytic effect Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000004640 cellular pathway Effects 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 238000001261 affinity purification Methods 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000002596 immunotoxin Substances 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 238000006276 transfer reaction Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000208422 Rhododendron Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020015265A JP7481852B2 (ja) | 2013-03-15 | 2020-01-31 | 免疫リガンド／ペイロード複合体の生産方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787371P | 2013-03-15 | 2013-03-15 | |
| EP13159484.8A EP2777714A1 (en) | 2013-03-15 | 2013-03-15 | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| EP13159484.8 | 2013-03-15 | ||
| US61/787,371 | 2013-03-15 | ||
| US201461939754P | 2014-02-14 | 2014-02-14 | |
| US61/939,754 | 2014-02-14 | ||
| PCT/EP2014/055173 WO2014140317A2 (en) | 2013-03-15 | 2014-03-14 | Method of producing an immunoligand/payload conjugate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020015265A Division JP7481852B2 (ja) | 2013-03-15 | 2020-01-31 | 免疫リガンド／ペイロード複合体の生産方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511279A JP2016511279A (ja) | 2016-04-14 |
| JP2016511279A5 true JP2016511279A5 (enExample) | 2017-02-02 |
| JP7213610B2 JP7213610B2 (ja) | 2023-01-27 |
Family
ID=47900856
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562218A Active JP7213610B2 (ja) | 2013-03-15 | 2014-03-14 | 免疫リガンド／ペイロード複合体の生産方法 |
| JP2020015265A Active JP7481852B2 (ja) | 2013-03-15 | 2020-01-31 | 免疫リガンド／ペイロード複合体の生産方法 |
| JP2022105670A Pending JP2022130634A (ja) | 2013-03-15 | 2022-06-30 | 免疫リガンド／ペイロード複合体の生産方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020015265A Active JP7481852B2 (ja) | 2013-03-15 | 2020-01-31 | 免疫リガンド／ペイロード複合体の生産方法 |
| JP2022105670A Pending JP2022130634A (ja) | 2013-03-15 | 2022-06-30 | 免疫リガンド／ペイロード複合体の生産方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9872923B2 (enExample) |
| EP (2) | EP2777714A1 (enExample) |
| JP (3) | JP7213610B2 (enExample) |
| CN (3) | CN113908291A (enExample) |
| AU (1) | AU2014230129B2 (enExample) |
| BR (2) | BR122021025118B1 (enExample) |
| CA (1) | CA2903581A1 (enExample) |
| DK (1) | DK2968583T3 (enExample) |
| ES (1) | ES3034413T3 (enExample) |
| HU (1) | HUE072754T2 (enExample) |
| IL (3) | IL240893B (enExample) |
| MX (1) | MX365547B (enExample) |
| PL (1) | PL2968583T3 (enExample) |
| SG (2) | SG10201903962PA (enExample) |
| WO (1) | WO2014140317A2 (enExample) |
| ZA (1) | ZA201506005B (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| EP2990423B1 (en) | 2013-04-25 | 2018-04-18 | AbTLAS Co., Ltd. | Method for refining protein including self-cutting cassette and use thereof |
| EP3517114A1 (en) * | 2014-04-29 | 2019-07-31 | Genequantum Healthcare (Suzhou) Co., Ltd. | New stable antibody-drug conjugate, preparation method and use thereof |
| JP6800154B2 (ja) | 2014-12-17 | 2020-12-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 結合形成酵素の活性アッセイ |
| EP3233906B1 (en) | 2014-12-17 | 2019-05-01 | F.Hoffmann-La Roche Ag | Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase |
| SG11201705041WA (en) * | 2014-12-23 | 2017-07-28 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| US20180028682A1 (en) | 2015-02-09 | 2018-02-01 | Nbe Therapeutics Ag | Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| MX376146B (es) | 2015-03-17 | 2025-03-07 | Regeneron Pharma | Reactivos de acilacion de aminoacidos y metodos para usar los mismos. |
| EP3353201B1 (en) * | 2015-09-25 | 2021-09-08 | F. Hoffmann-La Roche AG | Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof |
| JP6998862B2 (ja) | 2015-09-25 | 2022-02-04 | エフ．ホフマン－ラ ロシュ アーゲー | 可溶性ソルターゼａ |
| JP6895953B2 (ja) | 2015-09-25 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ソルターゼａを利用してチオエステルを作製するための方法 |
| EP3353314A1 (en) | 2015-09-25 | 2018-08-01 | H. Hoffnabb-La Roche Ag | Transamidation employing sortase a in deep eutectic solvents |
| AU2016345681A1 (en) | 2015-10-30 | 2018-05-10 | Nbe-Therapeutics Ag | Anti-ROR1 antibodies |
| WO2017072366A1 (en) * | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-mesothelin antibodies |
| EP3405496B1 (en) | 2016-01-20 | 2023-10-25 | University of Florida Research Foundation, Incorporated | Ror1 antibody compositions and related methods |
| CN109311982A (zh) | 2016-01-20 | 2019-02-05 | 斯克利普斯研究所 | Ror2抗体组合物和相关方法 |
| CN105925596A (zh) * | 2016-02-23 | 2016-09-07 | 上海交通大学 | 基于内含肽的药用重组蛋白的合成方法 |
| CN106397598B (zh) * | 2016-02-23 | 2020-07-14 | 上海交通大学 | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| KR20230082055A (ko) | 2016-06-17 | 2023-06-08 | 마젠타 테라퓨틱스 인코포레이티드 | 세포의 고갈을 위한 조성물 및 방법 |
| EP3272864A1 (en) | 2016-07-20 | 2018-01-24 | Paul Scherrer Institut | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| CN110381980A (zh) | 2017-01-06 | 2019-10-25 | 艾维迪提生物科学有限责任公司 | 核酸-多肽组合物以及诱导外显子跳读的方法 |
| IL268058B2 (en) | 2017-01-20 | 2023-09-01 | Magenta Therapeutics Inc | Compositions and methods for depleting cd137 plus cells |
| US20210139579A1 (en) | 2017-07-20 | 2021-05-13 | Nbe-Therapeutics Ag | Multispecific antibody product that binds to different ror1 epitopes |
| EP3655437A1 (en) | 2017-07-20 | 2020-05-27 | NBE-Therapeutics AG | Human antibodies binding to ror2 |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| KR20230008269A (ko) * | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
| CA3177215A1 (en) | 2017-09-19 | 2019-03-28 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US11110180B2 (en) | 2017-10-04 | 2021-09-07 | Avidity Biosciences Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| CN107759699A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd30抗原的转基因t细胞及其制备方法与应用 |
| CN118638788A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| US12037370B2 (en) | 2018-02-26 | 2024-07-16 | Research Institute At Nationwide Children's Hospital | Split-immunotoxins for boosting oncolytic virus toxicity |
| FI3765525T3 (fi) | 2018-03-13 | 2023-10-16 | Zymeworks Bc Inc | Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä |
| AU2019267011B2 (en) | 2018-05-10 | 2025-01-09 | Cis Biopharma Ag | Biocompatible copolymer containing multiple active agent molecules |
| CN108593909A (zh) * | 2018-05-23 | 2018-09-28 | 苏州立禾生物医学工程有限公司 | 一种定点标记免疫试剂的方法、标记免疫试剂及应用 |
| EP3828200A4 (en) * | 2018-07-09 | 2022-05-18 | National University Corporation Kumamoto University | Cyclic single-chain antibody |
| WO2020048876A1 (en) * | 2018-09-03 | 2020-03-12 | Technische Universitaet Muenchen | A double peptide tag combining reversibility and flexible functionalization |
| EP3858868B1 (en) | 2018-09-30 | 2025-10-22 | Jecho Laboratories, Inc. | Polypeptide composition |
| EP3636284A1 (en) | 2018-10-11 | 2020-04-15 | NBE Therapeutics AG | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| EP3647419A1 (en) | 2018-11-02 | 2020-05-06 | NBE Therapeutics AG | Sortase f and its use in methods for conjugation |
| WO2020102777A1 (en) | 2018-11-16 | 2020-05-22 | Virtuoso Binco, Inc. | Cd38 and icam1 antibodies and uses thereof |
| IL319265A (en) | 2018-12-21 | 2025-04-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and their uses |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| KR20220144753A (ko) * | 2019-03-19 | 2022-10-27 | 폴 슈레 앙스띠뛰 | 글리신 기반 링커를 사용한 트랜스글루타미나제 컨쥬게이션 방법 |
| CA3137715A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US12006499B2 (en) | 2019-06-06 | 2024-06-11 | Avidity Biosciences, Inc. | Una amidites and uses thereof |
| CA3142283A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| JP7590354B2 (ja) * | 2019-06-10 | 2024-11-26 | ストロ バイオファーマ インコーポレーテッド | 免疫調節物質抗体薬物コンジュゲートおよびその使用 |
| WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
| GB201914468D0 (en) | 2019-10-07 | 2019-11-20 | Crescendo Biologics Ltd | Binding Molecules |
| EP4051320A1 (en) | 2019-10-30 | 2022-09-07 | CIS Pharma AG | Biocompatible polymeric drug carriers for delivering active agents |
| JP7835441B2 (ja) | 2019-12-06 | 2026-03-25 | トゥルーバインディング，インコーポレイテッド | Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法 |
| CA3081503A1 (en) | 2019-12-06 | 2021-06-06 | Zymeworks Inc. | Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer |
| WO2021188390A1 (en) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| WO2021195469A1 (en) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| WO2022084560A1 (en) | 2020-10-25 | 2022-04-28 | Araris Biotech Ag | Means and methods for producing antibody-linker conjugates |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| AU2021423664B2 (en) | 2021-01-28 | 2026-02-05 | Genequantum Healthcare (Suzhou) Co., Ltd. | Ligase fusion proteins and applications thereof |
| CN117042806A (zh) | 2021-03-08 | 2023-11-10 | 启德医药科技（苏州）有限公司 | 抗体-免疫激动剂缀合物及其应用 |
| WO2022197945A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| WO2022195000A1 (en) * | 2021-03-18 | 2022-09-22 | Inofea Ag | Biocatalytical composition and use for generation of immunoligand-payload conjugates |
| AU2022259314A1 (en) | 2021-04-14 | 2023-11-30 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linkers, conjugates and applications thereof |
| CN115369127A (zh) * | 2021-05-18 | 2022-11-22 | 苏州有诺真生物科技有限公司 | 一种基于基因改造脊椎动物的携带通用定点偶联接口的抗体的制备方法 |
| JP2024526764A (ja) | 2021-07-13 | 2024-07-19 | トゥルーバインディング，インコーポレイテッド | タンパク質凝集を防止する方法 |
| WO2023014360A1 (en) * | 2021-08-05 | 2023-02-09 | Octagon Therapeutics, Inc. | Treatment and diagnosis of immune disorders relating to aberrant immune cells |
| CA3225815A1 (en) | 2021-08-13 | 2023-02-16 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN113777295B (zh) * | 2021-09-15 | 2024-03-19 | 江南大学 | 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用 |
| MX2024003266A (es) | 2021-09-16 | 2024-04-03 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral. |
| AU2022388722A1 (en) | 2021-11-09 | 2024-05-23 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
| KR20240125036A (ko) | 2021-12-23 | 2024-08-19 | 마이레큘, 인크. | 폴리뉴클레오타이드의 전달을 위한 조성물 |
| WO2023143319A1 (zh) * | 2022-01-28 | 2023-08-03 | 启德医药科技（苏州）有限公司 | 抗体药物偶联物、药物组合物及用途 |
| JP2025508823A (ja) | 2022-02-23 | 2025-04-10 | ブライト ピーク セラピューティクス エージー | 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用 |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| WO2024012566A2 (en) | 2022-07-15 | 2024-01-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
| KR20250054842A (ko) | 2022-07-29 | 2025-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법 |
| EP4568997A1 (en) | 2022-08-08 | 2025-06-18 | ATB Therapeutics | Humanized antibodies against cd79b |
| WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| EP4735602A2 (en) | 2023-06-27 | 2026-05-06 | Atrium Therapeutics, Inc. | Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract |
| CN121793987A (zh) | 2023-06-30 | 2026-04-03 | 艾维迪提生物科学公司 | 使用pln靶向性抗体-寡核苷酸缀合物的组合物和方法 |
| US20250197467A1 (en) | 2023-08-23 | 2025-06-19 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| US20250186597A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025083208A1 (en) | 2023-10-19 | 2025-04-24 | Boehringer Ingelheim International Gmbh | Synthesis of morpholine derivatives and compounds therefore |
| WO2026069134A1 (en) | 2024-09-26 | 2026-04-02 | Bright Peak Therapeutics Ag | Human therapy with il-18 immunocytokines |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA932523B (en) | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
| AU709988B2 (en) | 1995-06-07 | 1999-09-09 | Innogenetics N.V. | Immunotoxins specific for CD80 and CD86 expressing cells |
| JP2004515233A (ja) * | 2000-11-01 | 2004-05-27 | イルーシス セラポーティクス，インコーポレーテッド | タンパク質トランススプライシングによる二重特異性分子の作製方法 |
| DE10341812A1 (de) | 2003-09-10 | 2005-04-07 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| WO2005051976A2 (en) * | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| US7579187B2 (en) | 2004-09-06 | 2009-08-25 | Kyoma Hakko Kirin Co., Ltd. | Anti-A33 antibody |
| PL1819359T3 (pl) | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
| DE102005061934A1 (de) | 2005-12-23 | 2007-06-28 | Philipps-Universität Marburg | Verfahren zur Herstellung eines chemisch modifizierten Proteins |
| WO2007108013A2 (en) | 2006-03-22 | 2007-09-27 | National Institute Of Immunology | Novel bioconjugates as therapeutic agent and synthesis thereof |
| WO2008011157A2 (en) | 2006-07-20 | 2008-01-24 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| JP5618172B2 (ja) * | 2007-01-05 | 2014-11-05 | 国立大学法人東京大学 | 抗ｐｒｇ−３抗体を用いる癌の診断および治療 |
| WO2009052431A2 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| US8742076B2 (en) | 2008-02-01 | 2014-06-03 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| JP2011517555A (ja) * | 2008-03-14 | 2011-06-16 | ジェネンテック， インコーポレイテッド | 薬剤耐性に関連する遺伝的変異 |
| US8394604B2 (en) | 2008-04-30 | 2013-03-12 | Paul Xiang-Qin Liu | Protein splicing using short terminal split inteins |
| EP2277044B1 (en) * | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
| WO2010009124A2 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| WO2010087994A2 (en) * | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| CA2754531A1 (en) | 2009-03-06 | 2010-09-30 | Seattle Genetics, Inc. | Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
| CA2756246A1 (en) | 2009-04-08 | 2010-10-14 | Heinz Faulstich | Amatoxin-armed target-binding moieties for the treatment of cancer |
| SG176202A1 (en) | 2009-05-28 | 2011-12-29 | Glaxo Group Ltd | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye. |
| WO2011133704A2 (en) * | 2010-04-20 | 2011-10-27 | Whitehead Institute For Biomedical Researh | Modified polypeptides and proteins and uses thereof |
| ES2533710T3 (es) | 2010-12-02 | 2015-04-14 | Nerviano Medical Sciences S.R.L. | Proceso para la preparación de derivados de morfolinil antraciclina |
| EP2670440B1 (en) * | 2011-02-01 | 2018-09-05 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
| WO2012142659A1 (en) * | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| WO2013022808A2 (en) * | 2011-08-05 | 2013-02-14 | The University Of Chicago | Immunogenic protein conjugates and methods for making and using the same |
| KR20130046322A (ko) | 2011-10-27 | 2013-05-07 | 한국외국어대학교 연구산학협력단 | 식중독 세균 Salmonella enterica 탐지용 탐침자 및 그를 포함한 DNA 칩 |
| EP2852404B1 (en) | 2012-05-21 | 2017-07-26 | Genentech, Inc. | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE |
| JP2015519344A (ja) * | 2012-05-21 | 2015-07-09 | マサチューセッツ インスティテュート オブ テクノロジー | 炭疽菌防御抗原ポアを通しての非天然化学実体のトランスロケーション |
| SG11201407017WA (en) * | 2012-06-04 | 2014-12-30 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
| WO2014088928A1 (en) | 2012-12-03 | 2014-06-12 | President And Fellows Of Harvard College | Methods for making targeted protein toxins by sortase-mediated protein ligation |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| EP2990423B1 (en) | 2013-04-25 | 2018-04-18 | AbTLAS Co., Ltd. | Method for refining protein including self-cutting cassette and use thereof |
| GB2529356B (en) | 2013-04-28 | 2020-12-23 | Genequantum Healthcare Co Ltd | Novel linkers, coupling intermediates, conjugates, preparation method and application thereof |
-
2013
- 2013-03-15 EP EP13159484.8A patent/EP2777714A1/en not_active Withdrawn
-
2014
- 2014-03-14 EP EP14710285.9A patent/EP2968583B1/en active Active
- 2014-03-14 WO PCT/EP2014/055173 patent/WO2014140317A2/en not_active Ceased
- 2014-03-14 HU HUE14710285A patent/HUE072754T2/hu unknown
- 2014-03-14 DK DK14710285.9T patent/DK2968583T3/da active
- 2014-03-14 MX MX2015012983A patent/MX365547B/es active IP Right Grant
- 2014-03-14 CN CN202110883878.4A patent/CN113908291A/zh active Pending
- 2014-03-14 SG SG10201903962PA patent/SG10201903962PA/en unknown
- 2014-03-14 JP JP2015562218A patent/JP7213610B2/ja active Active
- 2014-03-14 CN CN201811043204.8A patent/CN109260478A/zh active Pending
- 2014-03-14 AU AU2014230129A patent/AU2014230129B2/en active Active
- 2014-03-14 SG SG11201507385YA patent/SG11201507385YA/en unknown
- 2014-03-14 BR BR122021025118-5A patent/BR122021025118B1/pt active IP Right Grant
- 2014-03-14 PL PL14710285.9T patent/PL2968583T3/pl unknown
- 2014-03-14 US US14/775,374 patent/US9872923B2/en active Active
- 2014-03-14 CN CN201480018071.2A patent/CN105142675B/zh active Active
- 2014-03-14 BR BR112015023589-1A patent/BR112015023589B1/pt active IP Right Grant
- 2014-03-14 ES ES14710285T patent/ES3034413T3/es active Active
- 2014-03-14 CA CA2903581A patent/CA2903581A1/en active Pending
-
2015
- 2015-08-19 ZA ZA2015/06005A patent/ZA201506005B/en unknown
- 2015-08-27 IL IL240893A patent/IL240893B/en active IP Right Grant
-
2017
- 2017-11-21 US US15/819,116 patent/US10864277B2/en active Active
-
2019
- 2019-08-01 IL IL268423A patent/IL268423B/en unknown
-
2020
- 2020-01-31 JP JP2020015265A patent/JP7481852B2/ja active Active
- 2020-06-29 US US16/915,343 patent/US11364301B2/en active Active
-
2021
- 2021-07-20 IL IL284979A patent/IL284979B/en unknown
-
2022
- 2022-06-13 US US17/839,395 patent/US11986535B2/en active Active
- 2022-06-30 JP JP2022105670A patent/JP2022130634A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11986535B2 (en) | Method of producing an immunoligand/payload conjugate | |
| Fairhead et al. | SpyAvidin hubs enable precise and ultrastable orthogonal nanoassembly | |
| JP7291395B2 (ja) | ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾 | |
| JP6590695B2 (ja) | アルブミン結合ポリペプチド | |
| JP2023540732A5 (enExample) | ||
| CN106795214B (zh) | 稳定化的基于纤连蛋白的支架分子 | |
| JPWO2016186206A1 (ja) | ＩｇＧ結合ペプチドによる抗体の特異的修飾 | |
| RU2714156C2 (ru) | С5-связующие полипептиды | |
| JP2023503868A5 (enExample) | ||
| JP2019508366A (ja) | トランスグルタミナーゼ認識部位を有するｆｋｂｐドメイン | |
| JP2016537981A5 (enExample) | ||
| WO2024084203A1 (en) | Single domain antibodies binding to albumin | |
| CN116355092A (zh) | 抗人血清白蛋白的纳米抗体及其应用 | |
| US20250101109A1 (en) | Anti-b7-h3 compounds and methods of use | |
| JP2022130332A (ja) | 抗ＳＡＲＳ－ＣｏＶ－２抗体 | |
| CN108300725A (zh) | 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用 | |
| JP2009542243A5 (enExample) | ||
| CN106928360B (zh) | 一种CD105纳米抗体Nb68 | |
| Fursova et al. | Refolding of scFv mini-antibodies using size-exclusion chromatography via arginine solution layer | |
| CN112979770B (zh) | 一种蛋白a突变体、融合蛋白和应用 | |
| CN120025428B (zh) | 一种靶向NS3a的纳米抗体及其应用 | |
| JP2025503924A (ja) | 抗ｂ７－ｈ３化合物及び使用方法 | |
| Gudipudi et al. | Section: bioprocessing and biological engineering gene fragment polymerization for increased yield of recombinant HIV fusion inhibitor enfuvirtide | |
| CN107964039A (zh) | 一种重组GP96-ScFv蛋白及其制备方法和应用 | |
| HK1226421B (en) | Binding polypeptides having a mutated scaffold |